Modulating Goal-directed Navigation Using Noninvasive Brain Stimulation
Launched by RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · Mar 24, 2023
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a technique called Transcranial Magnetic Stimulation (TMS) can affect the way our brain processes space during navigation tasks. The researchers want to see if TMS can change a specific brain signal that relates to how we understand our surroundings and make decisions based on rewards while navigating in virtual environments. Essentially, they are looking at whether stimulating certain areas of the brain can help improve our ability to navigate and make choices.
To participate in this trial, you need to be between 18 and 55 years old and in good physical and mental health. You also should not have a history of certain neurological disorders or conditions that could affect the brain, such as seizures or serious mental health issues. Participants will engage in virtual navigation tasks while receiving TMS treatment and will need to follow study procedures. Overall, this trial aims to better understand how brain stimulation might enhance our spatial navigation abilities.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Be between the ages of 18 and 55 years old.
- • 2. Not received substance abuse treatment within the previous 30 days.
- • 3. Be in stable mental and physical health.
- • 4. If female, test non-pregnant.
- • 5. No evidence of focal or diffuse brain lesion on MRI.
- • 6. Be willing to provide informed consent.
- • 7. Be able to comply with protocol requirements and likely to complete all study procedures.
- Exclusion Criteria:
- • 1. Contraindication to MRI (e.g., presence of metal in the skull, orbits or intracranial cavity, claustrophobia).
- • 2. Contraindication to rTMS (history of neurological disorder or seizure, increased intracranial pressure, brain surgery, or head trauma with loss of consciousness for \> 15 minutes, implanted electronic device, metal in the head, or pregnancy).
- • 3. History of autoimmune, endocrine, viral, or vascular disorder affecting the brain.
- • 4. History or MRI evidence of neurological disorder that would lead to local or diffuse brain lesions or significant physical impairment.
- • 5. Life time history of mental disorders such as: Bipolar Affective disorder (BPAD), Schizophrenia, Post-traumatic Stress disorder (PTSD) or Dementia or Major Depression.
- • uninterruptable central nervous system medication.
About Rutgers, The State University Of New Jersey
Rutgers, The State University of New Jersey, is a prestigious public research university renowned for its commitment to advancing medical science and public health. As a leading clinical trial sponsor, Rutgers leverages its extensive academic resources, cutting-edge facilities, and a diverse team of experts to conduct innovative research that addresses critical health challenges. The university fosters collaboration across disciplines, engaging in partnerships with healthcare institutions and industry leaders to enhance the development of novel therapies and improve patient outcomes. With a strong emphasis on ethical standards and regulatory compliance, Rutgers is dedicated to advancing clinical knowledge while prioritizing participant safety and well-being in all of its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Newark, New Jersey, United States
Patients applied
Trial Officials
Travis E Baker
Principal Investigator
Rutgers University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials